Review Article
Remdesivir use in the coronavirus disease 2019 pandemic: A mini-review

https://doi.org/10.1016/j.jmii.2020.09.002Get rights and content
Under a Creative Commons license
open access

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative viral pathogen of coronavirus disease 2019 (COVID-19), appears to have various clinical presentations and may result in severe respiratory failure. The global SARS-CoV-2-associated viral pneumonia pandemic was first reported in December 2019 in China. Based on known pharmacological mechanisms, many therapeutic drugs have been repurposed to target SARS-CoV-2. Among these drugs, remdesivir appears to be the currently most promising according to several clinical trials and reports of compassionate use. In this mini-review, we summarize the current evidence on the efficacy and challenges of remdesivir for the treatment of coronavirus disease 2019 (COVID-19).

Keywords

Severe acute respiratory syndrome coronavirus 2
Coronavirus disease 2019
Remdesivir
Compassionate use

Cited by (0)

1

Chih-Jen Yan and Yu-Jui Wei contributed equally to this work.